Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease

Mazyar Shadman

DOI: https://doi.org/10.6004/jnccn.2021.5110

IF: 12.6934

2021-11-01

Journal of the National Comprehensive Cancer Network

Abstract:Mantle cell lymphoma remains incurable despite recent treatment advances, and most patients experience relapsed/refractory disease. BTK inhibitors are the preferred choice in the relapsed setting, especially in patients with early relapse. For patients with high-risk features such as TP53 mutation, early referral for CAR T-cell therapy should be considered, even in those with stable disease on a BTK inhibitor. Patients without high-risk features may be monitored and initiate CAR T-cell therapy after clinical disease progression. CAR T-cell therapy is an effective treatment with high rate of complete remissions. For patients who do not achieve a complete remission 3 months after CAR-T therapy, bridging therapy with chemotherapy or targeted therapy agents and referral for allogeneic transplant are recommended.

oncology